Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PCI Biotech Holding ASA ( (DE:4QG) ) has shared an update.
PCI Biotech has decided to discontinue all research and development activities after an external evaluation of a new bioprocessing technology concluded without prospects for further collaboration, removing the key pillar that supported its limited ongoing operations. The company is now assessing a range of strategic alternatives, including a potential merger or a structured wind-up, against the backdrop of a critically weak liquidity position and uncertainty over securing additional financing, raising substantial doubt about its ability to remain a going concern and leaving shareholders facing heightened risk over the company’s future.
More about PCI Biotech Holding ASA
PCI Biotech Holding ASA is a Norwegian biotechnology company focused on developing bioprocessing and related R&D technologies for the life sciences sector, historically relying on external collaborations and partner interest to advance and finance its operations.
Average Trading Volume: 316,334
Current Market Cap: NOK9M
For an in-depth examination of 4QG stock, go to TipRanks’ Overview page.